Does the media favor PLRX or RNAC?

In the previous week, Cartesian Therapeutics had 9 more articles in the media than Pliant Therapeutics. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 6 mentions for Pliant Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Pliant Therapeutics' score of -0.09 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cartesian Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor PLRX or MGNX?

In the previous week, MacroGenics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for MacroGenics and 6 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat MacroGenics' score of -0.26 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PLRX or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Pliant Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -52.17% -40.46% Q32 Bio N/A 50.17% 29.49%

Does the media prefer PLRX or QTTB?

In the previous week, Pliant Therapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Pliant Therapeutics and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.17 beat Pliant Therapeutics' score of -0.09 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PYXS or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -173.46% -101.82% Pliant Therapeutics N/A -52.17% -40.46%

Does the media refer more to PYXS or PLRX?

In the previous week, Pyxis Oncology had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Pyxis Oncology and 6 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat Pyxis Oncology's score of -0.13 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AKBA or PLRX?

In the previous week, Akebia Therapeutics had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 11 mentions for Akebia Therapeutics and 6 mentions for Pliant Therapeutics. Akebia Therapeutics' average media sentiment score of -0.02 beat Pliant Therapeutics' score of -0.09 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pliant Therapeutics (PLRX) Competitors

$1.07 -0.01 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+0.93%)

As of 07:34 PM Eastern

Compare

PLRX vs. RNAC, MGNX, QTTB, PYXS, and AKBA

Should you buy Pliant Therapeutics stock or one of its competitors? Pliant Therapeutics's main competitors and comparable companies include Cartesian Therapeutics (RNAC), MacroGenics (MGNX), Q32 Bio (QTTB), Pyxis Oncology (PYXS), and Akebia Therapeutics (AKBA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Cartesian Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	41.93	-$149.34M	-$1.84	N/A
Cartesian Therapeutics	$1.48M	181.08	-$130.30M	-$5.94	N/A

Pliant Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Pliant Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Pliant Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 180.37%. Cartesian Therapeutics has a consensus price target of $32.60, indicating a potential upside of 268.78%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cartesian Therapeutics had 9 more articles in the media than Pliant Therapeutics. MarketBeat recorded 15 mentions for Cartesian Therapeutics and 6 mentions for Pliant Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.58 beat Pliant Therapeutics' score of -0.09 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cartesian Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 8.7% of Pliant Therapeutics shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cartesian Therapeutics beats Pliant Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to MacroGenics?

Pliant Therapeutics (NASDAQ:PLRX) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Pliant Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, MacroGenics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for MacroGenics and 6 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat MacroGenics' score of -0.26 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pliant Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 180.37%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 30.33%. Given Pliant Therapeutics' higher probable upside, equities analysts plainly believe Pliant Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MacroGenics has higher revenue and earnings than Pliant Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	41.93	-$149.34M	-$1.84	N/A
MacroGenics	$149.50M	1.79	-$74.62M	-$1.10	N/A

Pliant Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Pliant Therapeutics' return on equity of -52.17% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
MacroGenics	-8.70%	-106.38%	-20.52%

Summary

Pliant Therapeutics and MacroGenics tied by winning 8 of the 16 factors compared between the two stocks.

How does Pliant Therapeutics compare to Q32 Bio?

Pliant Therapeutics (NASDAQ:PLRX) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Q32 Bio has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	41.93	-$149.34M	-$1.84	N/A
Q32 Bio	$53.74M	8.39	$29.82M	$3.00	5.05

Pliant Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Pliant Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 180.37%. Q32 Bio has a consensus price target of $30.00, suggesting a potential upside of 98.02%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Pliant Therapeutics had 2 more articles in the media than Q32 Bio. MarketBeat recorded 6 mentions for Pliant Therapeutics and 4 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.17 beat Pliant Therapeutics' score of -0.09 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Q32 Bio's return on equity of 50.17% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Q32 Bio	N/A	50.17%	29.49%

Summary

Q32 Bio beats Pliant Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pliant Therapeutics' return on equity of -52.17% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-173.46%	-101.82%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Pyxis Oncology has higher revenue and earnings than Pliant Therapeutics. Pyxis Oncology is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	13.76	-$79.62M	-$1.31	N/A
Pliant Therapeutics	$1.58M	41.93	-$149.34M	-$1.84	N/A

Pyxis Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 149.17%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 180.37%. Given Pliant Therapeutics' higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Pyxis Oncology has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

In the previous week, Pyxis Oncology had 2 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Pyxis Oncology and 6 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of -0.09 beat Pyxis Oncology's score of -0.13 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pliant Therapeutics beats Pyxis Oncology on 8 of the 15 factors compared between the two stocks.

How does Pliant Therapeutics compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Akebia Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 324.02%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 180.37%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Akebia Therapeutics has higher revenue and earnings than Pliant Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A
Pliant Therapeutics	$1.58M	41.93	-$149.34M	-$1.84	N/A

Pliant Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Pliant Therapeutics' return on equity of -52.17% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Akebia Therapeutics had 5 more articles in the media than Pliant Therapeutics. MarketBeat recorded 11 mentions for Akebia Therapeutics and 6 mentions for Pliant Therapeutics. Akebia Therapeutics' average media sentiment score of -0.02 beat Pliant Therapeutics' score of -0.09 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Akebia Therapeutics beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRX vs. The Competition

Export

Metric	Pliant Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.88M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-0.72	10.67	269.06	25.28
Price / Sales	41.93	1,275.04	592.96	87.71
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.45	16.78	12.91	6.24
Net Income	-$149.34M	-$13.32M	$3.45B	$347.60M
7 Day Performance	1.90%	1.74%	1.12%	1.07%
1 Month Performance	-1.83%	1.60%	1.79%	1.03%
1 Year Performance	-32.06%	56.43%	67.69%	20.77%

Pliant Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRX Pliant Therapeutics	2.2337 of 5 stars	$1.07 -0.9%	$3.00 +180.4%	-32.5%	$66.88M	$1.58M	N/A	90	Earnings Report
RNAC Cartesian Therapeutics	2.3998 of 5 stars	$8.62 -1.6%	$32.60 +278.2%	-25.5%	$260.73M	$2.80M	N/A	64	Analyst Revision
MGNX MacroGenics	1.7901 of 5 stars	$4.06 -0.6%	$5.50 +35.6%	+145.8%	$257.74M	$149.50M	N/A	430	News Coverage Earnings Report Gap Down
QTTB Q32 Bio	4.5746 of 5 stars	$14.94 -4.7%	$30.00 +100.9%	+749.2%	$253.35M	$53.74M	4.98	39	Positive News
PYXS Pyxis Oncology	2.3 of 5 stars	$3.92 +2.2%	$7.50 +91.6%	+181.3%	$247.64M	$13.86M	N/A	60	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pliant Therapeutics (PLRX) Competitors

PLRX vs. RNAC, MGNX, QTTB, PYXS, and AKBA

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Summary

How does Pliant Therapeutics compare to MacroGenics?

Summary

How does Pliant Therapeutics compare to Q32 Bio?

Summary

How does Pliant Therapeutics compare to Pyxis Oncology?

Summary

How does Pliant Therapeutics compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pliant Therapeutics (PLRX) Competitors

PLRX vs. RNAC, MGNX, QTTB, PYXS, and AKBA

How does Pliant Therapeutics compare to Cartesian Therapeutics?

Which has better earnings and valuation, PLRX or RNAC?

Which has more risk and volatility, PLRX or RNAC?

Is PLRX or RNAC more profitable?

Do analysts recommend PLRX or RNAC?

Does the media favor PLRX or RNAC?

Do insiders and institutionals believe in PLRX or RNAC?

Summary

How does Pliant Therapeutics compare to MacroGenics?

Which has more risk and volatility, PLRX or MGNX?

Does the media favor PLRX or MGNX?

Do analysts rate PLRX or MGNX?

Do institutionals & insiders hold more shares of PLRX or MGNX?

Which has better valuation & earnings, PLRX or MGNX?

Is PLRX or MGNX more profitable?

Summary

How does Pliant Therapeutics compare to Q32 Bio?

Which has better valuation & earnings, PLRX or QTTB?

Which has more volatility & risk, PLRX or QTTB?

Do analysts recommend PLRX or QTTB?

Does the media prefer PLRX or QTTB?

Do insiders & institutionals have more ownership in PLRX or QTTB?

Is PLRX or QTTB more profitable?

Summary

How does Pliant Therapeutics compare to Pyxis Oncology?

Do institutionals and insiders have more ownership in PYXS or PLRX?

Is PYXS or PLRX more profitable?

Which has stronger valuation and earnings, PYXS or PLRX?

Do analysts recommend PYXS or PLRX?

Which has more risk and volatility, PYXS or PLRX?

Does the media refer more to PYXS or PLRX?

Summary

How does Pliant Therapeutics compare to Akebia Therapeutics?

Do analysts prefer AKBA or PLRX?

Which has higher valuation & earnings, AKBA or PLRX?

Is AKBA or PLRX more profitable?

Which has more risk & volatility, AKBA or PLRX?

Do institutionals and insiders have more ownership in AKBA or PLRX?

Does the media refer more to AKBA or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX vs. The Competition

Pliant Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools